Apollo Endosurgery, Inc. (NASDAQ:APEN) Files An 8-K Results of Operations and Financial ConditionItem 2.02Results of Operations and Financial Condition.
On July 12, 2017, Apollo Endosurgery, Inc. issued a press release announcing certain preliminary unaudited financial estimates for the three months ended June 30, 2017, including preliminary revenue and operating loss estimates and expected cash balance. The estimates are based on currently available information and do not present all necessary information for a complete understanding of our financial condition as of June 30, 2017 or our results of operations for the three months ended June 30, 2017. A copy of our press release is attached hereto as Exhibit 99.1.
The information in Item 2.02 of this report and the press release attached hereto as Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that Section or Sections11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by us, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit No. |
Description of Document |
|
99.1 |
Press release, issued by Apollo Endosurgery, Inc., dated July 12, 2017. |
Apollo Endosurgery, Inc. ExhibitEX-99.1 2 exhibit991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 AUSTIN,…To view the full exhibit click here
About Apollo Endosurgery, Inc. (NASDAQ:APEN)
Apollo Endosurgery, Inc., formerly Lpath, Inc., is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries. The Company’s products include ORBERA, LAP-BAND and OverStitch. The Company’s product, ORBERA, is a gastric balloon. The ORBERA Intragastric Balloon System is a weight loss aid for adults suffering from obesity. The LAP-BAND System is a minimally invasive procedure that offers weight loss. The LAP-BAND System is indicated for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope. OverStitch offers solutions for defects in both the upper and lower gastrointestinal tract.